MULTIPLE MYELOMA

Saad Usmani, MD, analyzes the efficacy and safety data results from the phase 3 MAIA study.

Saad Usmani, MD, discusses what first-line options are available for patients with multiple myeloma while highlighting the difficulties in defining high-risk characteristics associated with multiple myeloma.

Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma and describes the patient’s current prognosis.

Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma.

Rolling submission has been initiated for a Biologics License Application, submitting data to the FDA for the potential approval of ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma.

The FDA has approved selinexor in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.

In an interview with Targeted Oncology, Yi Lin, MD, PhD discussed the updated findings from the CRB-401 study of idecabtagene vicleucel as treatment of patients with relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, Mehmet Samur, PhD, discussed the investigation of high-dose melphalan following autologous stem cell transplant in patients with multiple myeloma and shared insights into how the ongoing questions can be explored in the future.

In an interview with Targeted Oncology, Jesus G. Berdeja, MD, discussed a subanalysis of the KarMMA study and updated results from CARTITUDE-1, which provide insights on the use CAR T-cell therapy in heavily pretreated patients with multiple myeloma, including the elderly and frail.

The combination of selinexor plus pomalidomide and low-dose dexamethasone led to favorable responses in a cohort of patients with heavily pretreated multiple myeloma, warranting further investigation of the regimen in a phase 3 trial.

A 20-mg 3-times-weekly or twice-weekly dosing schedule of panobinostat combined with subcutaneous bortezomib plus dexamethasone induced durable responses as treatment of patients with relapsed or refractory multiple myeloma and demonstrated an acceptable safety profile in the phase 2 PANORAMA 3 study.

Ixazomib in combination with lenalidomide plus dexamethasone achieved a clinically meaningful improvement of 13.5 months in the median progression-free survival as treatment of elderly patients with transplant-ineligible newly diagnosed multiple myeloma.

The combination of daratumumab with lenalidomide, bortezomib, and dexamethasone followed by maintenance therapy with daratumumab and lenalidomide improved response rates and depth of response rates with statistically significance as treatment of patients with transplant-eligible newly diagnosed multiple myeloma.

In the phase 3 APOLLO study, patients with relapsed/refractory multiple myeloma who had received 1 or more prior line of therapy had a significantly reduced the risk of progression or death by 37% when treated with the combination of subcutaneous daratumumab to pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone.

Idecabtagene vicleucel demonstrated clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma in the phase 2 KarMMA trial.

The novel oral cereblon E3 ligase modulator agent CC-92480 in combination with dexamethasone was found to be pharmacologically active with immunomodulatory activity at all doses as treatment of patients with relapsed/refractory multiple myeloma.

Patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel experienced rapid and clinically meaningful improvements in health-related quality of life and trends suggested that HRQoL benefits may be greater as responses to therapy deepen over time.

An overall response rate of 53% was observed with the first-of-its-kind FcRH5xCD3 bispecific antibody cevostamab along with manageable safety as treatment of patients with heavily pretreated patients with relapsed/refractory multiple myeloma who received active doses, according to results from a phase 1 dose-escalation study.

Encouraging response rates were observed in patients with relapsed or refractory multiple myeloma who were treated with off-the-shelf DuoBody IgG4 PAA binding antibody talquetamab. In addition, the agent showed a tolerable safety profile, according to early data from a phase 1 clinical trial.

Patients with relapsed or refractory multiple myeloma had deep and durable responses to the BCMA- and CD3-targeted bispecific monoclonal antibody REGN5458, early on in the course of treatment, according to findings from a first-in-human phase 1 study.

In a post hoc analysis of the DREAMM-2 trial, belantamab mafodotin achieved deep and durable responses with no notable alterations in its safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma who had received ≥7 prior therapies.

A novel BCMA and CD3 targeted bispecific T-cell engaging immunotherapy agent TNB-383B has demonstrated significant responses at higher dose levels and tolerability at all dose levels, including mild cases of cytokine release syndrome, according to initial results of a phase 1 trial presented during the 2020 American Society of Hematology Annual Meeting.

The ongoing phase 1/2 DREAMM-6 trial demonstrated clinical activity and a good safety profile with the combination of belantamab mafodotin, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma.

Ciltacabtagene autoleucel demonstrated a significant response rate and showed a manageable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

Enriching the CAR molecule bb2121 with the PI3K inhibitor bb007 improved response and extended duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.